These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19617224)

  • 1. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.
    Carrier L; Schlossarek S; Willis MS; Eschenhagen T
    Cardiovasc Res; 2010 Jan; 85(2):330-8. PubMed ID: 19617224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
    Schlossarek S; Mearini G; Carrier L
    J Mol Cell Cardiol; 2011 Apr; 50(4):613-20. PubMed ID: 21291890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice.
    Vignier N; Schlossarek S; Fraysse B; Mearini G; Krämer E; Pointu H; Mougenot N; Guiard J; Reimer R; Hohenberg H; Schwartz K; Vernet M; Eschenhagen T; Carrier L
    Circ Res; 2009 Jul; 105(3):239-48. PubMed ID: 19590044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome dysfunction in cardiomyopathies.
    Gilda JE; Gomes AV
    J Physiol; 2017 Jun; 595(12):4051-4071. PubMed ID: 28181243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
    Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy.
    Schlossarek S; Englmann DR; Sultan KR; Sauer M; Eschenhagen T; Carrier L
    Basic Res Cardiol; 2012 Jan; 107(1):235. PubMed ID: 22189562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.
    Sarikas A; Carrier L; Schenke C; Doll D; Flavigny J; Lindenberg KS; Eschenhagen T; Zolk O
    Cardiovasc Res; 2005 Apr; 66(1):33-44. PubMed ID: 15769446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy.
    Bahrudin U; Morisaki H; Morisaki T; Ninomiya H; Higaki K; Nanba E; Igawa O; Takashima S; Mizuta E; Miake J; Yamamoto Y; Shirayoshi Y; Kitakaze M; Carrier L; Hisatome I
    J Mol Biol; 2008 Dec; 384(4):896-907. PubMed ID: 18929575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy.
    Girolami F; Olivotto I; Passerini I; Zachara E; Nistri S; Re F; Fantini S; Baldini K; Torricelli F; Cecchi F
    J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):601-7. PubMed ID: 16858239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?
    Marston S; Copeland O; Gehmlich K; Schlossarek S; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):75-80. PubMed ID: 22057632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly.
    Niimura H; Patton KK; McKenna WJ; Soults J; Maron BJ; Seidman JG; Seidman CE
    Circulation; 2002 Jan; 105(4):446-51. PubMed ID: 11815426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction.
    Bahrudin U; Morikawa K; Takeuchi A; Kurata Y; Miake J; Mizuta E; Adachi K; Higaki K; Yamamoto Y; Shirayoshi Y; Yoshida A; Kato M; Yamamoto K; Nanba E; Morisaki H; Morisaki T; Matsuoka S; Ninomiya H; Hisatome I
    J Mol Biol; 2011 Nov; 413(4):857-78. PubMed ID: 21939669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies.
    Predmore JM; Wang P; Davis F; Bartolone S; Westfall MV; Dyke DB; Pagani F; Powell SR; Day SM
    Circulation; 2010 Mar; 121(8):997-1004. PubMed ID: 20159828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
    Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
    Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy.
    Chen SN; Czernuszewicz G; Tan Y; Lombardi R; Jin J; Willerson JT; Marian AJ
    Circ Res; 2012 Sep; 111(7):907-19. PubMed ID: 22821932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure.
    Arbustini E; Fasani R; Morbini P; Diegoli M; Grasso M; Dal Bello B; Marangoni E; Banfi P; Banchieri N; Bellini O; Comi G; Narula J; Campana C; Gavazzi A; Danesino C; Viganò M
    Heart; 1998 Dec; 80(6):548-58. PubMed ID: 10065021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.
    Hayashi T
    Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.
    Thottakara T; Friedrich FW; Reischmann S; Braumann S; Schlossarek S; Krämer E; Juhr D; Schlüter H; van der Velden J; Münch J; Patten M; Eschenhagen T; Moog-Lutz C; Carrier L
    J Mol Cell Cardiol; 2015 Oct; 87():214-24. PubMed ID: 26343497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy.
    Redwood CS; Moolman-Smook JC; Watkins H
    Cardiovasc Res; 1999 Oct; 44(1):20-36. PubMed ID: 10615387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point mutations in human beta cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: an ATP binding site change disrupts both thick and thin filaments, whereas hypertrophic cardiomyopathy mutations display normal assembly.
    Becker KD; Gottshall KR; Hickey R; Perriard JC; Chien KR
    J Cell Biol; 1997 Apr; 137(1):131-40. PubMed ID: 9105042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.